» Articles » PMID: 35609322

Chemokine (C-C Motif) Ligand 18/membrane-associated 3/forkhead Box O1 Axis Promotes the Proliferation, Migration, and Invasion of Intrahepatic Cholangiocarcinoma

Overview
Journal Bioengineered
Date 2022 May 24
PMID 35609322
Authors
Affiliations
Soon will be listed here.
Abstract

Phosphatidylinositol Transfer Protein, Membrane-Associated 3 (PITPNM3) often bind with chemokine (C-C motif) ligand 18 (CCL18) to promote tumor progression. However, the role of PITPNM3 in intrahepatic cholangiocarcinoma (ICC) is unclear. We first searched GEPIA database and detected the PITPNM3 expression using immunohistochemistry and real-time quantitative PCR. The results showed that PITPNM3 is high expression in ICC tissues and cells. Then we investigated the cell function of CLL18 and PITPNM3 through cell clone formation assay and transwell assay. The results indicated that CCL18 treatment promoted the proliferation, migration, and invasion of ICC cells. Silence of PITPNM3 reversed the effect of CCL18 on cell function. Simultaneously, we detected key protein expression of forkhead box O1 (FOXO1) and nuclear factor kappa B (NF-KB) through western blotting and found that CCL18 activated NF-KB pathway while inhibited FOXO1 pathway, the effect of which were attenuated by silence of PITPNM3. Finally, we confirmed which pathway affected the cell function using inhibitor of FOXO1 (AS1842856) and activator of NF-KB (Asatone). The results showed that AS1842856, not Asatone, relieved the inhibitory effect of si-PITPNM3 on the cell function of CCL18. In short, CCL18 treatment activated PITPNM3 to promote the proliferation, migration, and invasion of ICC via FOXO1 signaling pathway. These results provided a new insight for the diagnosis and therapy of ICC.

Citing Articles

Exosome-Delivered EGFR Induced by Acidic Bile Salts Regulates Macrophage M2 Polarization to Promote Esophageal Adenocarcinoma Cell Proliferation.

Chen C, Ding J, Ma Z, Xie Y, Zhang L, Zhu D Onco Targets Ther. 2024; 17:113-128.

PMID: 38384996 PMC: 10879628. DOI: 10.2147/OTT.S437560.


Long non-coding RNA MIR600HG as a ceRNA inhibits the pancreatic cancer progression through regulating the miR-1197/PITPNM3 axis.

Yang B, Jiao Z, Feng N, Zhang Y, Wang S Heliyon. 2024; 10(2):e24546.

PMID: 38312687 PMC: 10834820. DOI: 10.1016/j.heliyon.2024.e24546.


IRG1 restrains M2 macrophage polarization and suppresses intrahepatic cholangiocarcinoma progression via the CCL18/STAT3 pathway.

Zhou M, Yu H, Bai M, Lu S, Wang C, Ke S Cancer Sci. 2024; 115(3):777-790.

PMID: 38228495 PMC: 10920997. DOI: 10.1111/cas.16068.

References
1.
Korbecki J, Olbromski M, Dziegiel P . CCL18 in the Progression of Cancer. Int J Mol Sci. 2020; 21(21). PMC: 7663205. DOI: 10.3390/ijms21217955. View

2.
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

3.
Rahnemai-Azar A, Weisbrod A, Dillhoff M, Schmidt C, Pawlik T . Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis. Surg Oncol. 2017; 26(2):125-137. DOI: 10.1016/j.suronc.2016.12.009. View

4.
El-Diwany R, Pawlik T, Ejaz A . Intrahepatic Cholangiocarcinoma. Surg Oncol Clin N Am. 2019; 28(4):587-599. DOI: 10.1016/j.soc.2019.06.002. View

5.
Lin Z, Li W, Zhang H, Wu W, Peng Y, Zeng Y . CCL18/PITPNM3 enhances migration, invasion, and EMT through the NF-κB signaling pathway in hepatocellular carcinoma. Tumour Biol. 2015; 37(3):3461-8. DOI: 10.1007/s13277-015-4172-x. View